Form 4: Quanterix Director Granted 23,372 RSUs

Ivana Magovcevic-Liebisch, a Director at Quanterix Corp, was granted 23,372 restricted stock units vesting in January 2027.

Summary

• Director Ivana Magovcevic-Liebisch of Quanterix Corp (QTRX) was granted 23,372 restricted stock units (RSUs).
• The grant occurred on January 2, 2026, with an acquisition price of $0.00 per unit.
• These RSUs are scheduled to vest 100% on January 2, 2027.
• The grant was made in accordance with the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy.
• Following this transaction, Ivana Magovcevic-Liebisch beneficially owns a total of 43,607 securities, all of which are restricted stock units.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. This is a routine compensation filing, indicating standard corporate governance and director incentive alignment. It is not a major market-moving event but reflects ongoing operational practices.

Positives

• The grant of restricted stock units aligns the director's long-term interests with those of the shareholders.
• The transaction demonstrates the ongoing implementation of the company's established non-employee director compensation policy.

Risks

• The ultimate value of the restricted stock units is contingent upon the future market performance of Quanterix Corporation's common stock.
• The director must remain with the company until January 2, 2027, for the granted restricted stock units to fully vest.

Future Outlook

The vesting schedule for the restricted stock units on January 2, 2027, signifies a future commitment and aligns the director's financial interests with the company's long-term performance and shareholder value creation.

Industry Context

This Form 4 filing represents a routine insider transaction, specifically the grant of equity compensation to a non-employee director. Such practices are standard across publicly traded companies, particularly in the biotechnology and diagnostics sectors, to incentivize directors and align their interests with long-term company performance and shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) to non-employee directors is a common compensation practice in the life sciences industry, comparable to policies at companies like Bio-Techne Corporation or Guardant Health, Inc., aiming to foster long-term commitment and alignment.
• A $0.00 grant price for RSUs is standard for compensation awards, reflecting their nature as equity incentives rather than direct purchases.
• The one-year vesting period for director RSU grants (January 2026 to January 2027) is a typical structure designed to promote director retention and sustained engagement with company strategy.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grant to a director aligns their financial interests with shareholder value creation, potentially encouraging decisions that enhance long-term stock performance.

Next Steps

• The 23,372 restricted stock units are scheduled to vest on January 2, 2027.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of restricted stock units to a non-employee director as part of their compensation. Such grants are standard practice to align director incentives with shareholder interests and do not provide new information that would warrant a change in investment recommendation. The filing itself is not indicative of significant operational or financial changes for Quanterix Corp, thus a 'hold' recommendation remains appropriate based solely on this document.

Keywords

Quanterix, QTRX, SEC Form 4, Restricted Stock Units, RSU, Director Compensation, Insider Trading, Beneficial Ownership